iGluR Modulator
-
Risevistinel
0 ImagesCat. No.: HY-156634CAS No.: 2591344-26-0Synonyms: NYX-783Risevistinel (NYX-783) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease.
-
UBP710
0 ImagesCat. No.: HY-124264CAS No.: 1333111-40-2UBP710 is a selective NMDA receptor modulator. UBP710 displays greater activity in potentiating GluN2B-containing receptors than those containing GluN2A.
-
EMD 21657
0 ImagesCat. No.: HY-114987CAS No.: 61711-37-3EMD 21657 is a derivative of Piracetam (HY-B0585). EMD 21657 inhibits LOT compound action potential, and enhances the local anesthetic effect of Hexanol (HY-W032022). EMD 21657 exhibits hemolytic effect, and can be used in research about alcoholic encephalopathy syndrome.
-
NMDA receptor modulator 5
0 ImagesCat. No.: HY-143396CAS No.: 2758256-97-0NMDA receptor modulator 5 (Compound 195) is a potent NMDA receptor modulator. NMDA receptor modulator 5 can be used for neurological disorder research.
-
LSP-GR3
0 ImagesCat. No.: HY-148828CAS No.: 1235945-37-5LSP-GR3 is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate GluR alternative splicing to GluR3-flip expression throughout the CNS.
-
Dual Nav/NMDAR-IN-1
0 ImagesCat. No.: HY-184718Dual Nav/NMDAR-IN-1 (compound 11a) is a dual-target modulator of Nav and NMDAR. Dual Nav/NMDAR-IN-1 increases the thermal stability of Nav and NMDAR and slows their proteolytic degradation, indicating that it binds to both Nav and NMDAR simultaneously. Dual Nav/NMDAR-IN-1 exhibits anticonvulsant activity in a pentylenetetrazole-induced mouse model of seizures and can be used in epilepsy-related research.
-
PF-4778574
0 ImagesCat. No.: HY-14451CAS No.: 1219633-99-4PF-4778574 is a positive allosteric modulation of AMPA receptor with EC50 of 45 to 919 nM in differenct cells.
-
AMPA receptor modulator-5
0 ImagesCat. No.: HY-154798CAS No.: 2034182-22-2AMPA receptor modulator-5 (Example 217) is an AMPA receptor modulator. AMPA receptor modulator-5 can be used for research of neurological disease.
-
AMPA receptor modulator-7
0 ImagesCat. No.: HY-161090AMPA receptor modulator-7 (compound 36) is a modulator of AMPA receptor. AMPA receptor modulator-7 has oral activity and can penetrate the blood-brain barrier.
-
Piracetam (Standard)
0 ImagesPiracetam (Standard) is the analytical standard of Piracetam. This product is intended for research and analytical applications. Piracetam (UCB-6215) is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders.
-
Nevadistinel
0 ImagesCat. No.: HY-156626CAS No.: 2181816-92-0Synonyms: NYX-458; NYX-3054Nevadistinel (NYX-458; NYX-3054) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease.
-
NMDA receptor modulator 4
0 ImagesCat. No.: HY-143393CAS No.: 2758256-71-0NMDA receptor modulator 4 (Compound 169) is a potent NMDA receptor modulator. NMDA receptor modulator 4 can be used for neurological disorder research.
-
NMDA receptor modulator 3
0 ImagesCat. No.: HY-143391CAS No.: 2758256-02-7NMDA receptor modulator 3 (Compound 99) is a potent NMDA receptor modulator. NMDA receptor modulator 3 can be used for neurological disorder research.
-
NMDA receptor modulator 6
0 ImagesCat. No.: HY-143397CAS No.: 2758256-85-6NMDA receptor modulator 6 (Compound 183) is a potent NMDA receptor modulator. NMDA receptor modulator 6 can be used for neurological disorder research.
-
UBP512
0 ImagesCat. No.: HY-120074CAS No.: 1333112-78-9UBP512 is an NMDA receptor modulator with the activity to regulate NMDA receptor activity. UBP512 is a GluN2A-selective enhancer and GluN2C and GluN2D inhibitor, belonging to a new generation of NMDA receptor modulators, which may have potential effects on the study and inhibition of related neurological diseases.
-
SGE-201
0 ImagesCat. No.: HY-15786CAS No.: 35882-85-0SGE-201 is an allosteric modulator of N-methyl-D-aspartate receptors (NMDARs), demonstrating significant neuroprotective effects by enhancing NMDAR-mediated responses while differing in action among various blockers in neuronal networks.
-
Piracetam-d6
0 ImagesCat. No.: HY-B0585S1CAS No.: 2907016-93-5Synonyms: UCB-6215-d6Piracetam-d6 is deuterium labeled Piracetam. Piracetam (UCB-6215) is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders.
-
AMPA receptor modulator-6
0 ImagesCat. No.: HY-155628CAS No.: 516491-33-1AMPA receptor modulator-6 is an AMPA receptor positive allosteric modulator (PAM). AMPA receptor modulator-6 can be used in the study of neurological diseases.
-
Rapastinel acetate
0 ImagesCat. No.: HY-16728ACAS No.: 491872-39-0Synonyms: GLYX-13 acetateRapastinel (GLYX-13) acetate is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel acetate enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel acetate moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel acetate is applicable to the research of major depressive disorder and hepatocellular carcinoma.
-
GluN2B receptor modulator-1
0 ImagesCat. No.: HY-145370CAS No.: 2222010-71-9GluN2B receptor modulator-1 is a selective GluN2B negative allosteric modulator with an IC50 value of 31 nM.
